Jean-Marc Classe

9PUBLICATIONS
25CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Oncology and carcinogenesis not elsewhere classifiedCancer geneticsMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Oct 16, 2024
Eligibility for Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in Endocrine Receptor-Positive and HER2-Negative Early Breast Cancer by Age and Type of Surgery.

Gilles Houvenaeghel, Jean-Marc Classe, Marie-Pierre Chauvet

|Aug 10, 2024
Omission of Completion Axillary Lymph Node Dissection for Patients with Breast Cancer Treated by Upfront Mastectomy and Sentinel Node Isolated Tumor Cells or Micrometastases.

Gilles Houvenaeghel, Mellie Heinemann, Jean-Marc Classe

|Jan 19, 2024
Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients.

Barnabe Bouvarel, Oliver Colomban, Jean-Sebastien Frenel

|Sep 28, 2023
Negative Survival Impact of Occult Lymph Node Involvement in Small HER2-Positive Early Breast Cancer Treated by Up-Front Surgery.

Gilles Houvenaeghel, Monique Cohen, Marc Martino

|Sep 21, 2022
The need to tailor the omission of axillary lymph node dissection to patients with good prognosis and sentinel node micro-metastases.

Gilles Houvenaeghel, Alexandre de Nonneville, Nicolas Chopin

|Aug 26, 2022
Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database.

Marta Bini, Stanislas Quesada, Pierre Meeus

Pageof 2

Frequent Collaborators

3 joint publications

Alexandre de Nonneville

3 joint publications

Gilles Houvenaeghel

2 joint publications

Mellie Heinemann

2 joint publications

Loic Campion